United Kingdom · Question · Written question
UIN 41323
Sacituzumab Govitecan
Introduced
18 August 2021
Last action
8 September 2021 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
8 September 2021
Summary
To ask the Secretary of State for Health and Social Care, what recent representations he has made to representatives of the Medicines and Healthcare products Regulatory Agency (MHRA) on accelerating the approval of Trodelyn for treating metastatic triple
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
18 August 2021
Written question
To ask the Secretary of State for Health and Social Care, what recent representations he has made to representatives of the Medicines and Healthcare products Regulatory Agency (MHRA) on accelerating the approval of Trodelyn for treating metastatic triple
Source: Commons
8 September 2021
Answer
No such representations have been made. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for independently assessing the efficacy and safety of drugs before approval.
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2021-08-18/41323
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1351064
- uk · wq-1351064 · source updated 8 September 2021